BeneChill has raised a $13.5 million Series C financing led by New investor HealthCap (Stockholm). The other participants were Series A and B investors MedVenture Associates, the Solon Foundation and NGN Capital. Proceeds will be used to fund early commercialization of the RhinoChill device.
The company has recently completed a randomized PRINCE (Pre-Resuscitation Intra-Nasal Cooling Effectiveness) study of the RhinoChill device in cardiac arrest patients. The study will determine if the addition of intra-nasal cooling during resuscitation improves outcome following cardiac arrest over the hospital-based cooling alone. BeneChill will present the results of the PRINCE trial at the American Heart Association’s Scientific Sessions.